Antisense Transcription in Loci Associated to Hereditary Neurodegenerative Diseases.


Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 03 10 2018
accepted: 19 12 2018
pubmed: 6 1 2019
medline: 18 12 2019
entrez: 6 1 2019
Statut: ppublish

Résumé

Natural antisense transcripts are common features of mammalian genes providing additional regulatory layers of gene expression. A comprehensive description of antisense transcription in loci associated to familial neurodegenerative diseases may identify key players in gene regulation and provide tools for manipulating gene expression. We take advantage of the FANTOM5 sequencing datasets that represent the largest collection to date of genome-wide promoter usage in almost 2000 human samples. Transcription start sites (TSSs) are mapped at high resolution by the use of a modified protocol of cap analysis of gene expression (CAGE) for high-throughput single molecule next-generation sequencing with Helicos (hCAGE). Here we present the analysis of antisense transcription at 17 loci associated to hereditary Alzheimer's disease, Frontotemporal Dementia, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease. We focused our analysis on libraries derived from brain tissues and primary cells. We also screened libraries from total blood and blood cell populations in the quest for peripheral biomarkers of neurodegenerative diseases. We identified 63 robust promoters in antisense orientation to genes associated to familial neurodegeneration. When applying a less stringent cutoff, this number increases to over 400. A subset of these promoters represents alternative TSSs for 24 FANTOM5 annotated long noncoding RNA (lncRNA) genes, in antisense orientation to 13 of the loci analyzed here, while the remaining contribute to the expression of additional transcript variants. Intersection with GWAS studies, sample ontology, and dynamic expression reveals association to specific genetic traits as well as cell and tissue types, not limited to neurodegenerative diseases. Antisense transcription was validated for a subset of genes, including those encoding for Microtubule-Associated Protein Tau, α-synuclein, Parkinsonism-associated deglycase DJ-1, and Leucin-Rich Repeat Kinase 2. This work provides evidence for the existence of additional regulatory mechanisms of the expression of neurodegenerative disease-causing genes by previously not-annotated and/or not-validated antisense long noncoding RNAs.

Identifiants

pubmed: 30610612
doi: 10.1007/s12035-018-1465-2
pii: 10.1007/s12035-018-1465-2
pmc: PMC6614138
doi:

Substances chimiques

RNA, Antisense 0
RNA, Long Noncoding 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5392-5415

Références

J Biol Chem. 2000 Apr 14;275(15):11507-13
pubmed: 10753970
Nat Genet. 2003 Jun;34(2):157-65
pubmed: 12730694
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Nucleic Acids Res. 2004 Sep 08;32(16):4812-20
pubmed: 15356298
Science. 2005 Sep 2;309(5740):1564-6
pubmed: 16141073
Nat Genet. 2006 Jun;38(6):626-35
pubmed: 16645617
PLoS Genet. 2006 Apr;2(4):e47
pubmed: 16683030
BMC Genomics. 2007 Mar 15;8:74
pubmed: 17362513
Neurobiol Dis. 2007 Aug;27(2):238-47
pubmed: 17590346
Cell. 2007 Jun 29;129(7):1311-23
pubmed: 17604720
Hum Mol Genet. 2007 Dec 15;16(24):3174-87
pubmed: 17921506
Nature. 2008 Jan 10;451(7175):202-6
pubmed: 18185590
Genes Dev. 2008 Mar 15;22(6):756-69
pubmed: 18347095
Nat Med. 2008 Jul;14(7):723-30
pubmed: 18587408
Genes Dev. 2008 Aug 1;22(15):2085-92
pubmed: 18676813
Mol Cell. 2009 Mar 27;33(6):717-26
pubmed: 19217333
Nat Genet. 2009 May;41(5):553-62
pubmed: 19377474
PLoS One. 2010 Jan 11;5(1):e8658
pubmed: 20066053
Genome Biol. 2010;11(5):R56
pubmed: 20507594
Cell. 2010 Aug 6;142(3):409-19
pubmed: 20673990
Mol Cell. 2010 Sep 24;39(6):925-38
pubmed: 20797886
Cell. 2010 Oct 1;143(1):46-58
pubmed: 20887892
Nature. 2011 Feb 10;470(7333):284-8
pubmed: 21307942
Hum Mutat. 2011 Apr;32(4):E2079-90
pubmed: 21412942
Nature. 2011 Apr 7;472(7341):120-4
pubmed: 21423168
Nat Genet. 2011 May;43(5):429-35
pubmed: 21460840
Nat Genet. 2011 May;43(5):436-41
pubmed: 21460841
Genome Res. 2011 Jul;21(7):1150-9
pubmed: 21596820
Hum Mol Genet. 2011 Sep 1;20(17):3467-77
pubmed: 21672921
Neuron. 2011 Jun 23;70(6):1071-84
pubmed: 21689595
Am J Hum Genet. 2011 Jul 15;89(1):162-7
pubmed: 21763482
Am J Hum Genet. 2011 Jul 15;89(1):168-75
pubmed: 21763483
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Cell. 2011 Oct 14;147(2):344-57
pubmed: 22000013
Cell. 2011 Oct 14;147(2):358-69
pubmed: 22000014
Nat Biotechnol. 2012 Mar 25;30(5):453-9
pubmed: 22446693
Cell. 2012 May 11;149(4):819-31
pubmed: 22541069
Genome Res. 2012 Sep;22(9):1760-74
pubmed: 22955987
Genome Res. 2012 Sep;22(9):1775-89
pubmed: 22955988
Nature. 2012 Nov 15;491(7424):454-7
pubmed: 23064229
Nat Med. 2012 Dec;18(12):1812-9
pubmed: 23178247
RNA Biol. 2013 Mar;10(3):456-61
pubmed: 23324609
Science. 2013 Mar 15;339(6125):1335-8
pubmed: 23393093
Cell. 2013 Apr 25;153(3):707-20
pubmed: 23622250
Neuron. 2013 May 22;78(4):631-43
pubmed: 23623698
Nat Rev Drug Discov. 2013 Jun;12(6):433-46
pubmed: 23722346
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4968-77
pubmed: 24248382
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S23-8
pubmed: 24262182
Nat Struct Mol Biol. 2014 Feb;21(2):198-206
pubmed: 24463464
PLoS Comput Biol. 2014 Mar 20;10(3):e1003517
pubmed: 24651478
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Nature. 2014 Mar 27;507(7493):462-70
pubmed: 24670764
Nat Biotechnol. 2014 Mar;32(3):217-9
pubmed: 24727769
Hum Mol Genet. 2014 Dec 1;23(23):6139-46
pubmed: 24973356
Nucleic Acids Res. 2015 Jan;43(Database issue):D168-73
pubmed: 25332394
Nat Genet. 2014 Dec;46(12):1311-20
pubmed: 25383968
Nat Commun. 2014 Nov 12;5:5336
pubmed: 25387874
Nat Genet. 2015 Mar;47(3):199-208
pubmed: 25599403
Science. 2015 Feb 27;347(6225):1010-4
pubmed: 25678556
Genome Biol. 2015 Jan 05;16:22
pubmed: 25723102
Cell. 2015 Mar 12;160(6):1061-71
pubmed: 25728668
Nat Struct Mol Biol. 2015 May;22(5):370-6
pubmed: 25849144
Adv Drug Deliv Rev. 2015 Jun 29;87:15-24
pubmed: 26024979
Front Cell Neurosci. 2015 May 13;9:174
pubmed: 26029048
RNA Biol. 2015;12(8):771-9
pubmed: 26259533
Neurobiol Aging. 2015 Nov;36(11):2925-2931
pubmed: 26318290
Nat Neurosci. 2015 Nov;18(11):1556-8
pubmed: 26414614
BMC Genomics. 2015 Oct 28;16:876
pubmed: 26510930
Curr Opin Pharmacol. 2016 Feb;26:102-9
pubmed: 26609801
J Parkinsons Dis. 2016;6(1):109-17
pubmed: 26889637
Am J Hum Genet. 2016 Mar 3;98(3):500-513
pubmed: 26942284
Science. 2016 Mar 18;351(6279):1324-9
pubmed: 26989253
Acta Neuropathol Commun. 2016 Apr 14;4(1):37
pubmed: 27079381
Ann Neurol. 2016 Jun;79(6):991-9
pubmed: 27091628
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53
pubmed: 27190236
Sci Rep. 2016 Jun 06;6:27315
pubmed: 27265476
Genome Med. 2016 Jun 10;8(1):65
pubmed: 27287230
Nature. 2016 Sep 8;537(7619):239-243
pubmed: 27525555
Curr Neurol Neurosci Rep. 2016 Dec;16(12):107
pubmed: 27878525
Prog Neurobiol. 2017 Aug;155:194-211
pubmed: 27887908
Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):5-26
pubmed: 27943641
Neuron. 2017 Jan 4;93(1):66-79
pubmed: 28017471
PLoS Genet. 2016 Dec 29;12(12):e1006482
pubmed: 28033318
Genome Biol. 2017 Jan 30;18(1):22
pubmed: 28137300
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1509-E1518
pubmed: 28193854
Nature. 2017 Mar 9;543(7644):199-204
pubmed: 28241135
Exp Neurol. 2017 Dec;298(Pt B):191-201
pubmed: 28445716
Science. 2017 Nov 24;358(6366):1051-1055
pubmed: 29074580
EMBO Mol Med. 2018 Jan;10(1):107-120
pubmed: 29138229

Auteurs

Silvia Zucchelli (S)

Area of Neuroscience, SISSA, Trieste, Italy.
Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale (UPO), Novara, Italy.

Stefania Fedele (S)

Area of Neuroscience, SISSA, Trieste, Italy.

Paolo Vatta (P)

Area of Neuroscience, SISSA, Trieste, Italy.
Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genoa, Italy.

Raffaella Calligaris (R)

Area of Neuroscience, SISSA, Trieste, Italy.
Department of Medical, Surgical and Health Sciences, Clinical Neurology Unit, Cattinara University Hospital, Trieste, Italy.

Peter Heutink (P)

Section Medical Genomics, Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands.
Genome Biology of Neurodegenerative Diseases, Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE), Standort, Tübingen, Germany.
Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan.
RIKEN Omics Science Center, Yokohama, Japan.

Patrizia Rizzu (P)

Section Medical Genomics, Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands.
Applied Genomics for Neurodegenerative Diseases, Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE), Standort, Tübingen, Germany.

Masayoshi Itoh (M)

Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan.
RIKEN Omics Science Center, Yokohama, Japan.
RIKEN Preventive Medicine and Diagnosis Innovation Program, Wakō, Japan.

Francesca Persichetti (F)

Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale (UPO), Novara, Italy.

Claudio Santoro (C)

Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Piemonte Orientale (UPO), Novara, Italy.

Hideya Kawaji (H)

Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan.
RIKEN Omics Science Center, Yokohama, Japan.
RIKEN Preventive Medicine and Diagnosis Innovation Program, Wakō, Japan.
Preventive Medicine and Applied Genomics Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Timo Lassmann (T)

Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan.
RIKEN Omics Science Center, Yokohama, Japan.
Telethon Kids Institute, The University of Western Australia, 100 Roberts Road, Subiaco, WA, 6008, Australia.
Laboratory for Applied Computational Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Yoshihide Hayashizaki (Y)

RIKEN Omics Science Center, Yokohama, Japan.
RIKEN Preventive Medicine and Diagnosis Innovation Program, Wakō, Japan.

Piero Carninci (P)

Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan.
RIKEN Omics Science Center, Yokohama, Japan.
Laboratory for Transcriptome Technology, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Alistair R R Forrest (ARR)

Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Japan.
RIKEN Omics Science Center, Yokohama, Japan.
Laboratory for Genome Information Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Stefano Gustincich (S)

Area of Neuroscience, SISSA, Trieste, Italy. stefano.gustincich@iit.it.
Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genoa, Italy. stefano.gustincich@iit.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH